It’s not every day that a groundbreaking scientific discovery leads to a potential new class of medicines. But that’s exactly what’s happening at Alnylam. From the "Eureka!" moment of discovering RNA interference (RNAi) to the clinical progress and the potential patient impact of the development of RNAi therapeutics, this 15-year journey involved the passion and persistence of countless people—people who accepted the challenge and fought for the potential of RNAi every step of the way.

Vaccines

Proin id purus malesuada eros condimentum rutrum. Cras tincidunt convallis sapien ac interdum.

Small Molecules

Fusce rutrum orci quis massa elementum fermentum. Etiam fermentum felis a libero eleifend, eu gravida massa lacinia. Click Here

Antibiotics

Sed commodo lectus a odio suscipit, sed feugiat neque blandit. Morbi varius nunc tellus, nec mollis massa luctus eget. Aliquam erat volutpat. Nunc bibendum facilisis laoreet.

The First Breakthrough

RNAi (RNA interference) is first observed in plants and the first crucial breakthrough in understanding the RNAi mechanism came from studies in worms.

Recognizing Potential

The work of Andrew Fire and Craig Mello led to the recognition that long double-stranded RNA (dsRNA) could induce specific gene silencing

A Team Takes Shape

The work of Andrew Fire and Craig Mello led to the recognition that long double-stranded RNA (dsRNA) could induce specific gene silencing

The Highest Honor

Andrew Fire and Craig Mello are awarded the Nobel Prize.

Forming Strategy

Alnylam establishes an evolution in strategy with a focus on development and commercialization of investigational RNAi therapeutics in 3 Strategic Therapeutic Areas (STArs): Genetic Medicine, CardioMetabolic Diseases, and Hepatic Infectious Diseases.

A Plan for the Future

Alnylam launches Alnylam 2020—guidance that reflects the expected transition from late-stage clinical development to multiproduct commercial-stage with a sustainable development pipeline.

Vision Moving Forward

Alnylam CEO John Maraganore presents an updated company overview at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

New Title goes here

Alnylam establishes an evolution in strategy with a focus on development and commercialization of investigational RNAi therapeutics in 3 Strategic Therapeutic Areas (STArs): Genetic Medicine, CardioMetabolic Diseases, and Hepatic Infectious Diseases.